Your browser doesn't support javascript.
loading
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Fu, Xiaoyong; Jeselsohn, Rinath; Pereira, Resel; Hollingsworth, Emporia F; Creighton, Chad J; Li, Fugen; Shea, Martin; Nardone, Agostina; De Angelis, Carmine; Heiser, Laura M; Anur, Pavana; Wang, Nicholas; Grasso, Catherine S; Spellman, Paul T; Griffith, Obi L; Tsimelzon, Anna; Gutierrez, Carolina; Huang, Shixia; Edwards, Dean P; Trivedi, Meghana V; Rimawi, Mothaffar F; Lopez-Terrada, Dolores; Hilsenbeck, Susan G; Gray, Joe W; Brown, Myles; Osborne, C Kent; Schiff, Rachel.
  • Fu X; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030.
  • Jeselsohn R; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
  • Pereira R; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030.
  • Hollingsworth EF; Department of Pathology, Baylor College of Medicine, Houston, TX 77030.
  • Creighton CJ; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
  • Li F; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
  • Shea M; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
  • Nardone A; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
  • De Angelis C; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
  • Heiser LM; Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR 97239.
  • Anur P; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR 97239.
  • Wang N; Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR 97239.
  • Grasso CS; Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR 97239.
  • Spellman PT; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR 97239.
  • Griffith OL; McDonnell Genome Institute, Washington University, St. Louis, MO 63108.
  • Tsimelzon A; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
  • Gutierrez C; Department of Pathology, Baylor College of Medicine, Houston, TX 77030.
  • Huang S; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030.
  • Edwards DP; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030; Department of Pathology, Baylor College of Medicine, Houston, TX 77030.
  • Trivedi MV; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Pharmacy Practice and Translational Research, University of Houston, Houston, TX 77204; Department of Pharmacological and Pharm
  • Rimawi MF; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
  • Lopez-Terrada D; Department of Pathology, Baylor College of Medicine, Houston, TX 77030.
  • Hilsenbeck SG; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
  • Gray JW; Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR 97239.
  • Brown M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
  • Osborne CK; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030; Department of Medicine, Baylor College of Medici
  • Schiff R; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030; Department of Medicine, Baylor College of Medici
Proc Natl Acad Sci U S A ; 113(43): E6600-E6609, 2016 10 25.
Article en En | MEDLINE | ID: mdl-27791031
ABSTRACT
Forkhead box protein A1 (FOXA1) is a pioneer factor of estrogen receptor α (ER)-chromatin binding and function, yet its aberration in endocrine-resistant (Endo-R) breast cancer is unknown. Here, we report preclinical evidence for a role of FOXA1 in Endo-R breast cancer as well as evidence for its clinical significance. FOXA1 is gene-amplified and/or overexpressed in Endo-R derivatives of several breast cancer cell line models. Induced FOXA1 triggers oncogenic gene signatures and proteomic profiles highly associated with endocrine resistance. Integrated omics data reveal IL8 as one of the most perturbed genes regulated by FOXA1 and ER transcriptional reprogramming in Endo-R cells. IL-8 knockdown inhibits tamoxifen-resistant cell growth and invasion and partially attenuates the effect of overexpressed FOXA1. Our study highlights a role of FOXA1 via IL-8 signaling as a potential therapeutic target in FOXA1-overexpressing ER-positive tumors.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Regulación Neoplásica de la Expresión Génica / Interleucina-8 / Receptor alfa de Estrógeno / Factor Nuclear 3-alfa del Hepatocito / Transcriptoma Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Female / Humans Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Regulación Neoplásica de la Expresión Génica / Interleucina-8 / Receptor alfa de Estrógeno / Factor Nuclear 3-alfa del Hepatocito / Transcriptoma Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Female / Humans Idioma: En Año: 2016 Tipo del documento: Article